Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
2.8
Journals
CIMB
Special Issues
Cancer Biomarkers: Discovery and Applications
cimb-logo
Submit to Special Issue Submit Abstract to Special Issue Review for CIMB Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Cancer Biomarkers: Discovery and Applications

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 2349

Special Issue Editor

Dr. Po-Ming Chen

E-Mail Website
Guest Editor
1. Research Assistant Center, Show Chwan Memorial Hospital, Changhua 500, Taiwan
2. Department of Nursing, Central Taiwan University of Science and Technology, Taichung 406, Taiwan
Interests: cancer biomarkers; cancer

Special Issue Information

Dear Colleagues,

The emergence of personalized medicine, driven by the integration of biomarkers, represents a major breakthrough in cancer management. This shift toward precision therapy enhances treatment effectiveness while minimizing unnecessary side effects, offering patients more tailored care based on the specific biology of their cancer. Molecular technologies such as next-generation sequencing, single-cell analysis of circulating tumor cells, and multifunctional multicolor flow cytometry, among others, are vital for early cancer prevention and the optimization of therapeutic management. By enabling more accurate and timely diagnoses, these tools improve patient prognoses and open new possibilities for proactive cancer care. This Special Issue will offer a comprehensive review of the current state of cancer biomarker development and examine how emerging technologies and biomarkers are poised to revolutionize cancer care.

Dr. Po-Ming Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer biomarkers
  • precision medicine
  • prevention
  • prognosis
  • diagnosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 15867 KiB  
Article
SPP1 mRNA Expression Is Associated with M2 Macrophage Infiltration and Poor Prognosis in Triple-Negative Breast Cancer
by Yu-Chia Chen, Chia-Ching Chen, Rong-Fu Chen, Hsin-Hung Chen and Po-Ming Chen
Curr. Issues Mol. Biol. 2024, 46(12), 13499-13513; https://doi.org/10.3390/cimb46120806 - 25 Nov 2024
Cited by 1 | Viewed by 1747
Abstract
(1): Triple-negative breast cancer (TNBC) is an especially aggressive form of breast cancer defined by a poor prognosis and a lack of effective treatment options. There is a pressing need for validated predictive and prognostic biomarkers to assist in making treatment decisions and [...] Read more.
(1): Triple-negative breast cancer (TNBC) is an especially aggressive form of breast cancer defined by a poor prognosis and a lack of effective treatment options. There is a pressing need for validated predictive and prognostic biomarkers to assist in making treatment decisions and improve the prognostic accuracy for patients with this challenging disease. (2): We analyzed the RNA-seq data from three TNBC tissue samples alongside their corresponding normal tissues. Gene set enrichment analysis (GSEA) identified potential pathways. Additionally, we examined SPP1 mRNA expression datasets available in the Kaplan–Meier plotter and investigated the SPP1 protein expression patterns in our own tissue microarray cohort via immunohistochemistry. (3): The results revealed that genes associated with the Toll-like receptor signaling pathway showed a significant increase in activity in TNBC tissues when compared to normal breast tissues. Furthermore, SPP1 expression was found to be elevated in the TCGA TNBC dataset and correlated with a poor prognosis. This pattern was corroborated at the protein level in our TNBC tissue cohort; however, SPP1 protein expression did not demonstrate a significant impact on survival. Notably, SPP1 mRNA expression was strongly linked to tumor-associated macrophages (TAMs), particularly the M2 macrophage subtype, indicating a substantial association in the context of TNBC. (4): Our research highlights the significance of SPP1 mRNA as a key prognostic indicator and a potential molecular responder for TNBC treatment utilizing targeted therapies that focus on Toll-like receptor signaling pathways. Full article
(This article belongs to the Special Issue Cancer Biomarkers: Discovery and Applications)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 535 KiB  
Review
Revolution of Circulating Tumor DNA: From Bench Innovations to Bedside Implementations
by Xuehan Yan, Juncheng Su and Zheng Wang
Curr. Issues Mol. Biol. 2025, 47(6), 428; https://doi.org/10.3390/cimb47060428 - 6 Jun 2025
Viewed by 89
Abstract
Circulating tumor DNA (ctDNA), a newly developed cancer biomarker, consists of single- or double-stranded DNA fragments that are shed from tumor cells in primary or metastatic sites. They are released into peripheral blood and exhibit distinct characteristics associated with cancer, even in the [...] Read more.
Circulating tumor DNA (ctDNA), a newly developed cancer biomarker, consists of single- or double-stranded DNA fragments that are shed from tumor cells in primary or metastatic sites. They are released into peripheral blood and exhibit distinct characteristics associated with cancer, even in the early stages. With advancements in technology, ctDNA detection has become more diverse and precise, including digital Polymerase Chain Reaction (dPCR) and next-generation sequencing (NGS), among others. As a chronic disease that develops over an extended period, early detection is crucial for the accurate diagnosis and treatment of cancer and can significantly improve patient prognosis. Therefore, analyzing ctDNA features is important. Additionally, ctDNA can be used to assess post-surgical minimal residual disease (MRD), aiding in treatment decisions. Overall, ctDNA plays a crucial role in the progression of cancer and its treatment. This review summarizes the sources and features of ctDNA, the analytical techniques used, and its application in both solid and non-solid tumors. Full article
(This article belongs to the Special Issue Cancer Biomarkers: Discovery and Applications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop